Abivax SA (ABVX) Stock Forecast & Price Target

Abivax is supported by highly compelling Phase 3 ABTECT-Maintenance data, where obefazimod produced clinical remission of 51.3% and 50.8% versus 10.4% for placebo, with similarly strong endoscopic remission and improvement across both doses. The durability profile also strengthens the case, as longer-term follow-up showed 68% clinical remission at Week 144 by NRI and 85% observed among patients remaining on 25 mg, with no new safety signals emerging over up to seven years of cumulative treatment. Fundamentally, the company combines a differentiated oral mechanism, broad efficacy even in advanced-therapy-experienced and prior JAK-failure patients, and about €1.2B of cash that supports runway into 4Q29 while it advances Crohn’s data in mid-2027 and commercialization preparation.

Abivax is facing a negative fundamental outlook because obefazimod’s encouraging UC data still look like a monotherapy in a market increasingly moving toward combination regimens, where peers such as AbbVie and JNJ are already showing additive efficacy in refractory disease. The company also faces a more crowded oral IBD landscape, with Gilead’s emvistegrast posting competitive Week 12 results, while Abivax has no announced clinical combination program and only expects preclinical combination data by YE26, leaving it behind on the next likely efficacy driver. Although cash of €402.4MM plus €767.1MM of July net proceeds extends runway into 4Q29, the stock still appears to embed a favorable 4Q27 UC approval and limited commercial share in later-line settings, with significant upside dependent on much better-than-expected CD data or combination progress.